- Erratum: Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
-
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
-
Cardiovasc Prev Pharmacother. 2020;2(1):31. Published online January 31, 2020
-
DOI: https://doi.org/10.36011/cpp.2020.2.e1
-
Corrects: Cardiovasc Prev Pharmacother 2019;1(1):30
-
PDF
- Aspirin Has a Neutral Effect in Preventing Future Cardiovascular Events in Vasospastic Angina
-
Kwan Yong Lee, Dong Il Shin, Sung Ho Her, Seung Hwan Han, Youngkeun Ahn, Dong-Soo Kim, Dong-Ju Choi, Hyuck Moon Kwon, Hyeon-Cheol Gwon, Seung-Woon Rha, Sang-Ho Jo, Sung Cil Lim, Jun-Pyo Myong, Sang Hong Baek
-
Cardiovasc Prev Pharmacother. 2019;1(1):30-42. Published online July 31, 2019
-
DOI: https://doi.org/10.36011/cpp.2019.1.e4
-
Correction in: Cardiovasc Prev Pharmacother 2020;2(1):31
-
3,864
View
-
15
Download
-
2
Citations
-
Abstract
PDF
- Background
The aim of this multi-center prospective registry study was to evaluate the clinical efficacy of low-dose aspirin in vasospastic angina (VA) patients for the prevention of future cardiovascular events.
Methods A total of 1,717 patients with positive and intermediate results of an intracoronary ergonovine provocation test in the VA in Korea registry (n=2,960) were classified into 100 mg/day aspirin intake (aspirin, n=743) and no-aspirin intake (control, n=974) groups. The primary end-point was a composite of major adverse cardiac events (MACEs) including cardiac death, new-onset arrhythmia, and acute coronary syndrome.
Results The median follow-up duration was 2.0 years (25–75th, interquartile range 0.9–3.0 years). Cumulative composite MACE in the propensity score matched-pair cohort (n=1,028) was 3.6%. There was no significant difference in composite MACE between the aspirin and control groups (3.1% vs. 4.1%; hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.61–2.26; p=0.623). A sensitivity analysis of only the VA-positive population showed these results to be consistent. Even for patients with minimal organic stenosis (n=369), aspirin usage was not related to the incidence of a composite MACE (HR, 1.61; 95% CI, 0.55–4.72; p=0.380).
Conclusions Low-dose aspirin does not protect against future cardiovascular events in VA patients, even patients who combine with minimal coronary artery stenosis.
-
Citations
Citations to this article as recorded by
- Characteristics of Patients with Vasospastic Angina in Korea: Data from a Large Cohort (VA-KOREA)
Sung Eun Kim, Sang-Ho Jo, Won-Woo Seo, Min-Ho Lee, Hyun-Jin Kim, Seong-Sik Cho, Kwan Yong Lee, Dong-Soo Kim, Tae-Hyun Yang, Sung-Ho Her, Seung Hwan Han, Byoung-Kwon Lee, Youngkeun Ahn, Seung-Woon Rha, Hyeon-Cheol Gwon, Dong-Ju Choi, Sang Hong Baek Cardiovascular Prevention and Pharmacotherapy.2021; 3(3): 47. CrossRef - Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1. CrossRef
|